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ABSTRACT 3 
Over the last decades, novel therapeutic tools for osteochondral regeneration have arisen 4 
from the combination of mesenchymal stromal cells (MSCs) and highly specialized 5 
smart biomaterials, such as hydrogel-forming elastin-like recombinamers (ELRs), which 6 
could serve as cell-carriers. Herein, we evaluate the delivery of xenogeneic human 7 
MSCs (hMSCs) within an injectable ELR-based hydrogel carrier for osteochondral 8 
regeneration in rabbits. First, a critical-size osteochondral defect was created in the 9 
femora of the animals and subsequently filled with the ELR-based hydrogel alone or 10 
with embedded hMSCs. Regeneration outcomes were evaluated after three months by 11 
gross assessment, magnetic resonance imaging and computed tomography, showing 12 
complete filling of the defect and the de novo formation of hyaline-like cartilage and 13 
subchondral bone in the hMSC-treated knees. Furthermore, histological sectioning and 14 
staining of every sample confirmed regeneration of the full cartilage thickness and early 15 
subchondral bone repair, which was more similar to the native cartilage in the case of 16 
the cell-loaded ELR-based hydrogel. Overall histological differences between the two 17 
groups were assessed semi-quantitatively using the Wakitani scale and found to be 18 
statistically significant (p < 0.05). Immunofluorescence against a human mitochondrial 19 
antibody three months post-implantation showed that the hMSCs were integrated into 20 
the de novo formed tissue, thus suggesting their ability to overcome the interspecies 21 
barrier. Hence, we conclude that the use of xenogeneic MSCs embedded in an ELR-22 
4 
 
 
based hydrogel leads to the successful regeneration of hyaline cartilage in osteochondral 1 
lesions. 2 
KEYWORDS 3 
hyaline cartilage; human mesenchymal stromal cells; elastin-like recombinamers; 4 
osteochondral regeneration; xenotransplantation 5 
  6 
5 
 
 
INTRODUCTION 1 
Osteochondral injuries are a frequent source of pain and disability and can even result in 2 
secondary osteoarthritis.1,2 This disease has an enormous economic impact in developed 3 
countries, mostly due to ageing.3,4 One of the main issues in this regard is that articular 4 
cartilage possesses limited regeneration ability due to its avascularity and the cellular 5 
and interstitial structure that sustains the biomechanical requirements of joints.5 As 6 
such, it is easy to understand the efforts of orthopedic surgeons in developing novel 7 
therapies in this field.6 8 
The development of novel tissue-engineering methods7,8 involving mesenchymal 9 
stromal cell (MSC) therapy in combination with highly specialized biomaterials has 10 
opened up a broad field for the study of articular cartilage regeneration.9 MSCs are 11 
pluripotent cells that can easily be isolated and expanded in vitro. Furthermore, these 12 
cells can differentiate into diverse cell types (including chondrocytes and osteocytes) 13 
and exert immunomodulatory properties, which makes them good candidates for the 14 
treatment of musculoskeletal lesions.10,11 There are different auto-, allo- and xenogeneic 15 
sources of MSCs. However, whereas the first two options offer an immunologically 16 
safer approach, the latter increases the availability of MSCs enormously. Indeed, there 17 
are numerous studies describing the successful use of xenogeneic MSCs in different 18 
hosts.12 Since pre-differentiated cells have been proposed to induce immunological 19 
reactions in xenotransplantation models,13 differentiation may be induced in vivo in the 20 
presence of some specific endogenous factors in the niche where MSCs are 21 
implanted.14,15 22 
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In contrast, the application of a single suspension of MSCs may lead to poor retention 1 
and viability of cells,16,17 therefore the use of scaffolds is highly recommended in order 2 
to increase the persistence and engraftment of the implanted cells at the site of injury. 3 
To this end, biomaterials that mimic the extracellular matrix (ECM) and acquire a 3D 4 
structure that could be re-populated by cells might be very helpful. Such materials 5 
should also be compatible with non-invasive techniques, as is the case for injectable 6 
hydrogels. Over the last few decades recombinant DNA techniques have proven to be 7 
very powerful tools for the development of novel protein biomaterials that are able to 8 
self-assemble into different structures, such as hydrogels.18,19 These biomaterials 9 
include elastin-like recombinamers (ELRs),20 the composition of which is based on 10 
repetition of the VPGXG pentapeptide found in natural elastin, in which X (guest 11 
residue) can be any amino acid except L-proline. ELRs show thermosensitivity, which 12 
is characterized by a temperature known as the transition temperature (Tt), above which 13 
ELRs assemble hydrophobically, undergoing a phase transition, whereas they remain 14 
soluble at lower temperatures,21,22 thus permitting a homogeneous embedding of MSCs. 15 
These ELR molecules can self-assemble into hydrogels above the Tt, i.e., at 16 
physiological temperature, when designed with a very specific composition,23 thus 17 
allowing the use of the cell-scaffold system in arthroscopy or in injectable therapies, 18 
where they adopt the shape of the injured tissue. As a result of their recombinant nature, 19 
further genetic modification of these ELRs by addition of the well-known RGD cell-20 
adhesion sequence, which promotes specific cell attachment via integrins,24 leads to an 21 
injectable scaffold that provides a cell-friendly environment. 22 
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With regard to the tracking of cartilage regeneration, non-invasive imaging techniques 1 
that allow patients to be monitored are highly encouraged. Magnetic resonance imaging 2 
(MRI) is the most frequently used imaging method for the evaluation of chondral 3 
injuries,25-27 and this technique is complemented with computed tomography (CT) when 4 
subchondral bone has also been damaged.28 5 
Despite the ability to monitor evolution of the injured tissue in vivo, histology is still 6 
essential to demonstrate the regenerative potential of novel treatments when tested in 7 
animals. In fact, several methods, such as those of O’Driscoll or Wakitani, aim to 8 
quantitatively assess articular cartilage repair by microscopic observation, thereby 9 
proposing a more efficient approach for the comparison of different therapies.29 10 
In this work, we hypothesized that human MSCs (hMSCs) embedded in an ELR-based 11 
hydrogel resembling the ECM would be able to regenerate an osteochondral critical-size 12 
defect in a xenotransplantation model in rabbits. Herein, we show results from gross 13 
assessment, imaging techniques (MRI and 3D CT) and microscopic evaluation using the 14 
Wakitani histological scoring system. 15 
MATERIALS AND METHODS 16 
2.1. Ethical approval 17 
All procedures regarding collection of hMSCs specified below were approved by the 18 
Ethics Committee of the University Hospital of Salamanca (Spain) and were also in 19 
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accordance with the Declaration of Helsinki (1975), as revised in 2000. Informed 1 
written consent was obtained from all subjects included in the study. 2 
All animal experiments were conducted in accordance with the institutional guidelines 3 
for the care and use of experimental animals of the University of Salamanca (Spain) in 4 
accordance with Directive 2010/63/EU (Resolution Number 2010/2/23). 5 
2.2. Human mesenchymal stromal cell (hMSC) collection 6 
A volume of 5 mL of bone marrow was obtained from six healthy donors (mean age 55 7 
years), by conventional iliac crest aspiration, at the University Hospital of Salamanca. 8 
Low density mononuclear cells (MNCs) were isolated using a Ficoll-Paque gradient 9 
(Biochrom KG, Berlin, Germany) and plated at a cell density of 106 MNC/cm2 on a 10 
polystyrene surface in DMEM (Gibco BRL, Paisley, UK) containing 5% platelet lysate, 11 
obtained as reported previously.30 Culture flasks were maintained in a humidified 12 
incubator at 37 °C and 5% CO2, with medium replacement twice a week, removing non-13 
adherent hematopoietic cells. The cell layer was trypsinized at 80% confluence and cells 14 
were subcultured at a cell density of 2.5·103 MNC/cm2. Methods and the results of 15 
MSC characterization, according to previous studies, are summarized in the 16 
Supplementary Material (Supplementary Methods).31-33 17 
2.3. ELR design, bioproduction and characterization 18 
The elastin-like recombinamer (ELR) used in this work was genetically engineered as 19 
described elsewhere19 and provided by Technical Proteins Nanobiotechnology (TPNBT) 20 
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S.L. (Spain). Briefly, the ELR was recombinantly bioproduced in Escherichia coli in a 1 
15-L bioreactor (Applikon Biotechnology, Netherlands) and purified by several cooling 2 
and heating purification cycles (Inverse Transition Cycling) following centrifugation. 3 
The ELR sequence and its description can be found in the Supplementary Information 4 
(Supplementary Methods and Table S-1). 5 
In order to study the stability of the resulting hydrogels, they were formed by dissolving 6 
the ELR in cold phosphate buffered saline (PBS, pH 7.4) at a concentration of 75 7 
mg/mL in glass vials, and heated to 37 °C for 15 minutes. Another vial was kept at 4 °C 8 
during that time. Both vials were then placed face down and photographs taken for 9 
comparison. 10 
2.4. In vivo experimental model 11 
Six male New Zealand white rabbits with an age of 6 months and an average weight of 12 
3.45 kg were used for the creation and treatment of the osteochondral defects. Animals 13 
were anesthetized intramuscularly with xylazine (5 mg/kg) and ketamine (35 mg/kg), 14 
then both knees were shaved and cleaned. A parapatellar incision of the skin was 15 
performed under sterile conditions in order to expose the distal femur. A 4x4 mm full-16 
thickness critical-size osteochondral lesion was created with a drill. The defect was deep 17 
enough to reach the osteochondral bone in every case. Immediately afterwards, a cold 18 
solution containing 0.5·106 hMSCs embedded in 2 mL of the hydrogel solution (75 19 
mg/mL, culture medium) was used to completely fill the defect of the right knee (n = 6), 20 
whereas the hydrogel under the same conditions but without cells was placed in the left 21 
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knee to serve as control (n = 6). The wound was closed after less than 1 minute, and the 1 
hydrogel fully solidified and adapted itself to the surface of the lesion, as confirmed by 2 
visual observation, after coming into contact with the animal tissue, at a temperature 3 
above the Tt of the ELR. Gentamicin (5 mg/kg) was administered after the surgical 4 
procedure to avoid infection. All animals were fed and watered ad libitum during the 5 
study period and maintained in individual cages. 6 
Animals were euthanized with pentobarbital (120 mg/kg) at three months post-treatment 7 
and the distal femora were extracted for further analysis. 8 
2.5. MRI and 3D CT 9 
Whole legs from two animals were used for image collection using a 1.5 Tesla MRI 10 
instrument (Signa LX version 9.1, General Electric), with the sequences Oblique 3D 11 
Fast Spoiled Gradient Echo (FRPGR) Special and 3D Spoiled Gradient (3D SPGR). 12 
Two other specimens were used for extraction of both femoral condyles for further 13 
image analysis using multi-slice helical CT (Aquilion 16, Toshiba, Japan), obtaining 14 
axial sequences of 0.5 mm thickness on the bone window and multi-slice 3D 15 
reconstructions in the sagittal and coronal planes. 16 
2.6. Histological analysis 17 
Extracted samples were fixed in 4% formaldehyde and 0.2% picric acid in PBS 0.1 M 18 
(pH 7.3) at 4 °C. They were subsequently processed as described in the Supplementary 19 
Information. 20 
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A blind macro- and microscopic analysis was performed on the samples by a trained 1 
histologist. Samples from each rabbit (n = 6 for each group) were classified on the basis 2 
of their modified Wakitani score34 (Table S-2, maximum score of 15) and inter-group 3 
comparisons were performed using the non-parametric Kruskal–Wallis test, with a p-4 
value < 0.05 indicating statistically significant differences. 5 
To evaluate the survival of human MSCs, a mouse monoclonal antibody against a 65 6 
kD mitochondrial membrane protein specifically expressed in human cells (MAB1273, 7 
Millipore) was used, followed by a secondary antibody, namely donkey anti-mouse IgG, 8 
conjugated with Cy3 (Jackson Immunoresearch Europe, Ltd., U.K). The combination 9 
with 4',6-diamidino-2-phenylindole (DAPI), a fluorescent stain that binds strongly to A-10 
T rich regions in DNA, allowed all nuclei from both human and rabbit cells to be 11 
stained, and thus the xenogeneic cells in the regenerated tissue to be observed in 12 
comparison with host cells. 13 
Images were taken under similar conditions of exposure and time for every sample, as 14 
stated in the Supplementary Information. 15 
RESULTS 16 
3.1. ELR bioproduction and characterization 17 
The ELR was successfully bioproduced in E. coli, purified by ITC and stored 18 
lyophilized at -20 °C until further use. The bioproduction yield was found to be an 19 
average of 200 mg ELR/L of culture. 20 
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SDS-PAGE and MALDI-TOF confirmed the purity, integrity and molecular weight of 1 
the ELR, which coincided with the theoretical value. Thus, the experimental molecular 2 
weight was found to be 112,253 Da, while the theoretical value was 112,270 Da (Figure 3 
S-1). Moreover, the Tt was found to be 15.3 °C in PBS (Figure S-2), which means that 4 
hydrogels are formed at physiological temperature upon ELR transition. The 1H NMR 5 
spectrum (Figure S-3 and Table S-3) and amino acid analysis (Table S-4) showed the 6 
absence of contaminants in the final ELR product. 7 
To macroscopically assess hydrogel formation, the ELR was dissolved at 4 °C and then 8 
warmed to 37 °C. The vial containing the hydrogel was then placed upside-down and 9 
the hydrogel found to be formed and stable, in other words it did not fall from the 10 
bottom of the tube or dilute in an aqueous solvent (Figure 1). 11 
 12 
Figure 1. ELR dissolved at 4 ºC (A) and hydrogel formed at 37 ºC (B), inverted to show 13 
the hydrogel state and its stability. 14 
3.2. Macroscopic evaluation 15 
A. Control group (ELR) 16 
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A partially regenerated whitish region could be observed macroscopically in the 1 
extracted femora, with this area being paler than the surrounding normal cartilage. 2 
Furthermore, the appearance thereof was not smooth and it presented a fibrotic surface, 3 
with protrusions (Figure 2, red arrows) projecting slightly from the rest of the articular 4 
surface (Figure 2, A2 and B2), thus differing from the appearance of non-injured 5 
cartilage. 6 
B. Experimental group (ELR + hMSCs) 7 
Regenerated tissue with a smooth and bright appearance was observed in all cases. The 8 
injured region could be recognized by its more greyish colour in comparison with the 9 
regenerated cartilage. Moreover, the regenerated tissue was well integrated into the 10 
surrounding chondral tissue, with continuity between the two structures (Figure 2, A1 11 
and B1, black arrows), thus resembling the situation found in non-injured cartilage. 12 
 13 
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Figure 2. Images showing the comparison between femurs extracted from the same 1 
animals (A and B) treated either with hMSCs combined with the ELR-based hydrogel 2 
(experimental group) (A1, B1), or with the ELR-based hydrogel alone (control group) 3 
(A2, B2). Defects are indicated with black and red arrows for the experimental and the 4 
control group, respectively. 5 
3.3. Image analysis 6 
3.3.1. MRI 7 
A. Control group (ELR) 8 
The 3D SPGR (Figure 3A) magnetic resonance sequence showed articular cartilage loss 9 
(yellow arrow) and an underlying bone oedema of approximately 3 mm along the major 10 
axis in both samples studied. Similarly, axial 3D FSPGR (Figure 3B) showed a 11 
discontinuity in the articular cartilage of the femoral condyle (long yellow arrow) with 12 
underlying bone lesion (short yellow arrow). 13 
B. Experimental group (ELR + hMSCs) 14 
Regenerated articular cartilage could be observed in all sequences acquired, showing a 15 
healthy subchondral bone (3D SPGR, Figure 3C, yellow arrow), while the condyle 16 
surface showed no fractures or traces of bone oedema in any case (3D FSPGR, Figure 17 
3D, yellow arrow highlighting regenerated defect), thus suggesting complete restoration 18 
of the injured tissue in every sample. 19 
15 
 
 
 1 
Figure 3. MRI analysis of femurs extracted from rabbits in the control group (ELR 2 
hydrogel, A and B) and experimental group (ELR hydrogel + hMSCs, C and D). A and 3 
C, and B and D correspond to the 3D SPGR and 3D FSPGR sequences, respectively. 4 
3.3.2. 3D CT 5 
A. Control group (ELR) 6 
A 3D reconstruction of the femoral condyles (Figure 4 (top)) showed a bone defect of 7 
up to 3x3 mm in the transverse and anteroposterior planes, with articular cartilage loss, 8 
thus indicating a partially repaired osteochondral lesion (red outlines). These findings 9 
were confirmed in the sagittal and axial plane images (Figure 4B and C, respectively). 10 
B. Experimental group (ELR + hMSCs) 11 
The osteochondral defect was imperceptible in the specimen from the experimental 12 
group (Figure 4, bottom), thus indicating an almost fully regenerated injury (Figure 4A). 13 
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Sagittal (Figure 4B) and axial (Figure 4C) plane images corroborated the result found in 1 
the 3D reconstruction, thereby also confirming the MRI findings. 2 
 3 
Figure 4. 3D CT reconstructions (A) and sagittal and axial slices (B and C) of femurs 4 
from rabbits in the control group (top) and experimental group (bottom). Marked 5 
defects are highlighted in red. 6 
3.4. Histological analysis 7 
Toluidine blue stain was used to clarify the distribution of cells and collagen fibres in 8 
the extracellular matrix, as well as cell morphology, thus allowing the observation of 9 
osteoblasts and osteocytes, together with bone lamellas and bone marrow cells, the 10 
cytoplasm of which was stained a deep blue colour. Furthermore, this metachromatic 11 
colorant allowed the identification of newly formed bone tissue (stained violet), with the 12 
chondral matrix being stained into reddish and purple hues. In addition, Von Kossa 13 
staining allowed calcified regions to be differentiated from other tissue by its dark 14 
brown colour. 15 
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3.4.1. Microscopic evaluation 1 
The regenerated tissue at the articular surface of samples from the control group 2 
exhibited a minimal thickness in comparison with adjacent non-injured articular 3 
cartilage (Figure 5). Moreover, this tissue showed a fibrotic appearance, similar to the 4 
features of fibrocartilage, arranged on a base of subchondral bone trabeculae that is 5 
mostly regenerated. This fibrocartilage-like tissue was composed of small egg-shaped 6 
cells, the major axis of which was oriented parallel to the articular surface, following the 7 
orientation of the fibres that compose the matrix in which the cells are embedded. 8 
However, this tissue was not found to be integrated with the surrounding hyaline 9 
cartilage present at the surface of non-injured cartilage. 10 
 11 
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Figure 5. Toluidine blue (left) and Von Kossa (right) staining of non-injured tissue (A-1 
D) and samples from the control (ELR, E-H) and experimental groups (ELR + hMSCs, 2 
I-L). Scale bar corresponds to 1 mm for I and K, 500 µm for A and C, 250 µm for B, D, 3 
E, G, J and L, and 125 µm for F and H. 4 
In contrast, coronal sections from samples from the experimental group (ELR + 5 
hMSCs) showed the osteochondral defect area to be entirely filled with a tissue 6 
identified as hyaline cartilage. This regenerated cartilage displayed a smooth and regular 7 
surface and was completely integrated with the adjacent non-injured cartilage, with no 8 
signs of discontinuity in any case. The different layers comprising de novo formed 9 
cartilage could also be clearly observed, showing no structural differences with respect 10 
to healthy cartilage. The defect in the subchondral bone beneath the regenerated 11 
articular cartilage was filled with a tissue with the structural and staining features of 12 
cartilage. Regions of hypertrophied chondrocytes could be found towards the edges of 13 
the cartilage near the subchondral bone, and the neighbouring matrix was moderately 14 
calcified, which was identified as an endochondral ossification process. These areas 15 
continued to the edges of the injured zone until they reached trabeculae from intact bone 16 
tissue, with no interruption with the adjacent bone. Filling of cartilaginous tissue was 17 
observed in the bone area of the lesion. A further demonstration of these results can be 18 
seen in Figure 6, in which a well regenerated articular cartilage (white outline) can be 19 
seen together with ossification areas below it (yellow outline), showing a similar 20 
structure to that found in native osteochondral tissue. 21 
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 1 
Figure 6. Von Kossa staining of a sample from the experimental group showing 2 
complete regeneration of articular cartilage (white dotted line) with areas of ossification 3 
(yellow dotted line) beneath the cartilage. Scale bar corresponds to 250 µm. 4 
3.4.2. Histological evaluation using the modified Wakitani grading scale 5 
A statistical blind study of the histological sections using the modified Wakitani scale 6 
gave a total score of 13.7 points for the defects from the experimental group (ELR + 7 
hMSCs), which is close to the score for healthy cartilage (15 points). In contrast, 8 
evaluation of the defects from the control group (ELR) gave a score of 7 points, with a 9 
statistically significant difference (p < 0.01) in the overall score between experimental 10 
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and control groups (Figure 7). Complete scores from the histological evaluation are 1 
shown in Table S-5 (Supplementary Material). 2 
 3 
Figure 7. Comparison between the histological scores obtained for the experimental 4 
(ELR + hMSCs) and control (ELR) groups, according to the modified Wakitani scale 5 
(*p < 0.01). 6 
3.4.3. Immunofluorescence analysis 7 
The immunofluorescence results, obtained by combining antibodies versus the human 8 
mitochondrial marker (red) and DAPI staining (blue), showed that hMSCs were 9 
involved in regeneration of the osteochondral defect, since cells have a chondrocyte-like 10 
morphology and arrangement, integrating the de novo formed tissue. This was only 11 
observed in sections from the experimental group, with no fluorescence being detected 12 
in the control group (Figure 8). 13 
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 1 
Figure 8. Immunofluorescence images to human mitocondrial marker, in red (A, D), 2 
DAPI, in blue (B, E), an merged images (C, F) taken from animals of the control group 3 
(ELR, A-C) and the experimental group (ELR + hMSC, D-E) showing the presence of 4 
hMSCs in the regenerated tissue of animals from the experimental group. Scale bar = 5 
125 µm for A-C, and 50 µm for D-F. 6 
DISCUSSION 7 
We have described the use of MSCs encapsulated within an ELR-based hydrogel to 8 
regenerate an osteochondral defect for the first time. Although there are previous studies 9 
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regarding the treatment of this type of lesions with ELRs, none of them included any 1 
type of cells inside the scaffold, and the outcomes observed were not very promising, 2 
being similar to those for the control group.35,36 Furthermore, both studies involved the 3 
use of chemically cross-linked hydrogels, which makes them harder to handle and may 4 
lead to toxic sub-products. Moreover, in one case the ELR-based hydrogel was not 5 
formed in situ, which compromises the adaptability to the shape of the defect, and the 6 
use of genipin as cross-linker increases the expense considerably.35 In our case the 7 
network sustaining the hydrogel is formed via physical cross-linking (hydrophobic 8 
interactions) above the Tt, e.g., at physiological temperature. As such, this system is 9 
highly suitable for non-invasive techniques due to its injectability below the Tt. In 10 
addition, biofunctionalization of the ELR by the genetic fusion of a 12-mer peptide 11 
containing the RGD cell-adhesion sequence provides a cell-friendly environment for 12 
hMSCs. 13 
This approach represents a significant advance in the regeneration of osteochondral 14 
injuries because it is widely thought that biomaterials should simulate the properties of 15 
cartilage and subchondral bone, thus requiring biphasic37 or even triphasic38 scaffolds 16 
that must comprise biomaterials with different features to recapitulate the osteochondral 17 
interface and promote healing. However, here we show that the use of an injectable 18 
ELR-based single hydrogel is an efficient approach in regenerative medicine as this 19 
biomaterial serves only as a temporary microenvironment and does not need to have the 20 
same properties as the native tissues.39 21 
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Regeneration of the injured cartilage was successfully studied using a 1.5T MRI 1 
instrument, without contrast agents, similarly to analogous models.40,41 This study 2 
showed almost complete regeneration of the damaged tissue in the experimental group 3 
(ELR + hMSCs) after three months. It was also possible to study the development of 4 
subchondral bone with high precision by CT, thereby demonstrating regeneration of the 5 
tissue and emphasizing the importance of this procedure for assessing regeneration of 6 
osteochondral injuries in combination with MRI. This may allow more invasive 7 
methods, such as biopsy, to be avoided.42 8 
With respect to the histological findings, the experimental (ELR + hMSCs) and control 9 
(ELR) groups obtained 13.7 and 7 points, respectively, on the Wakitani scale, at three 10 
months post-implantation. We chose this grading scale due to its simplicity in 11 
comparison to other systems. Taking into account that the maximum score on this scale 12 
is 15 points (Table S-2), we can calculate the percentage regeneration as the ratio 13 
between the obtained and maximum values. Thus, we obtained a value of 91% for the 14 
experimental group and 47% for the control group. This means that we can compare the 15 
outcomes of osteochondral regeneration with MSCs (auto-, allo- or xenotransplanted), 16 
at the same timepoint (3 months), even when different grading scales and/or animal 17 
models are used, especially when considering that regeneration may vary between 18 
species. For instance, Nakamura et al. created an osteochondral defect in both legs of 19 
pigs, subsequently treating one knee with allogeneic MSCs while leaving the other as a 20 
control. Their results, according to the same histological scoring scale as used in our 21 
work, showed 57% regeneration for the experimental joint and 10% regeneration for the 22 
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control joint.34 In another study, Koga et al. implanted allogeneic MSCs within a 1 
collagen scaffold in rabbit knees, with the collagen hydrogel alone as control. Their 2 
histological scoring (unmodified Wakitani scale) gave a regeneration of 89% and 21% 3 
for the experimental and control groups, respectively.43 Similarly, Mazaki et al. 4 
described the use of allogeneic MSCs embedded in a gelatin hydrogel, obtaining 66% 5 
regeneration in this case and 42% when using the gelatin hydrogel alone (modified 6 
ICRS scale).44 7 
Other hydrogels have also been used in osteochondral regeneration. For instance, Miller 8 
et al. studied the ability of an injectable peptide hydrogel combined with chondrogenic 9 
factors and allogeneic MSCs to regenerate an osteochondral defect in rabbits, finding 10 
poorer repair when MSCs were included in the hydrogel.45 For their part, D’Este et al. 11 
evaluated an injectable thermoresponsive hyaluronan/pNIPAAm hydrogel in an 12 
analogous system, but not including MSCs. Their results showed better regeneration in 13 
the non-treated (75%) than in the hydrogel-treated defects (70%).46 Although these 14 
authors claim that this biomaterial is biocompatible and does not interfere with the 15 
intrinsic healing response, its implantation does not result in an improvement and thus it 16 
is not very likely to be accepted by clinicians. In another study, Levingstone et al. 17 
demonstrated the use of collagen-based scaffolds combined with other biomaterials 18 
(multi-phasic scaffold) to recapitulate the osteochondral interface, without including 19 
MSCs.47 They reported 80% regeneration of defects treated with the cited scaffold, as 20 
opposed to the 44% observed in the control non-treated defects. In contrast, Pulkkinen 21 
et al. observed no significant differences in terms of histological assessment between 22 
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treatment of an osteochondral defect with recombinant human type II collagen 1 
hydrogels embedding autologous chondrocytes and the spontaneously repaired tissue.48 2 
In the light of all these comparisons (see Table S-6, Supplementary Information), we 3 
can conclude that our preliminary study represents a novel non-invasive therapy for the 4 
treatment of injuries affecting articular cartilage with very promising results that are 5 
better than those found in the literature in every case. One of the reasons that could 6 
explain the differences between our study and others is the use of a bioactive ELR-7 
based hydrogel containing RGD cell-adhesion sequences, which therefore serves as an 8 
ECM-like vehicle for hMSCs and provides a cell-friendly environment that supports 9 
their regenerative potential. However, due to the subjectivity of histological scoring, 10 
particular care must be taken when drawing conclusions from a direct comparison of the 11 
results from different studies. 12 
It is important to highlight the xenogeneic nature of the animal model used in this study. 13 
This kind of cell therapy has been proposed as a replacement for allogeneic and 14 
autologous bone and cartilage implantation, which have some limitations, especially a 15 
shortage of donor tissue and the time-consuming nature of the procedure. Xenogeneic 16 
MSCs have been used as undifferentiated cells, such as in our study, showing better 17 
regeneration outcomes and higher survival than differentiated hMSCs.13,49 However, 18 
Jang et al. showed good regeneration (75%) when including chondrocyte-differentiated 19 
hMSCs in a biphasic composite (hydroxyapatite and platelet-rich fibrin glue) scaffold.50 20 
Similarly, the literature review by Li et al. concluded that porcine MSCs downregulate 21 
T cell responses in vitro, which could also be reproduced in vivo, hence being a feasible 22 
26 
 
 
approach in clinical applications.12 In contrast, Pei et al. reported a detrimental effect of 1 
xenotransplanted MSCs in comparison to their non-treated control.14 In this case, we 2 
believe that the influence of the matrix used as cell carrier was not considered as a 3 
source of this effect and should be studied in more detail. 4 
Moreover, the use of xenogeneic hMSCs allowed us to track the implanted cells in the 5 
articular cartilage of the rabbit using a novel immunofluorescence technique that 6 
involves the use of an antibody towards a specific human mitochondrial marker, thus 7 
discerning between transplanted and host cells. This method allowed us to detect viable 8 
and engrafted hMSCs after three months, thus proving that the ELR-based hydrogel can 9 
be used as a successful cell carrier in which cells can differentiate and regenerate 10 
damaged tissue. Our results therefore confirm that MSCs can overcome inter-species 11 
barriers. In addition, we observed that the implanted human cells show a chondrocyte-12 
like shape and arrangement, similar to that of native cartilage, thus suggesting that 13 
differentiation into a chondral cell lineage has taken place, which is in good agreement 14 
with previous findings by Koga et al.43 15 
In summary, this work shows the potential effectiveness of a tissue-engineering 16 
approach for regeneration of a critical-size osteochondral defect, in terms of 17 
morphology and structure, upon combining hMSCs with a recombinantly developed 18 
ELR-based cell-carrier hydrogel. The comparison with other approaches found in the 19 
literature shows a more hyaline-like regeneration, and the closest previous result (89%, 20 
by Koga et al.) involves the use of a non-injectable scaffold, which limits its application 21 
in non-invasive therapies. This system provides a bioactive scaffold in which cells may 22 
27 
 
 
be embedded for accurate delivery to the injury site to promote tissue-engineered 1 
regeneration of native-like hyaline cartilage. Further studies will be performed to 2 
evaluate the functionality of regenerated articular cartilage through biomechanical tests, 3 
and to determine the biochemical composition of the repaired tissue before translating 4 
this system into larger animal models or humans. 5 
ACKNOWLEDGMENTS 6 
The authors are grateful for funding from the European Commission (NMP-2014-7 
646075, HEALTH-F4-2011-278557, PITN-GA-2012-317306 and MSCA-ITN-2014-8 
642687), the MINECO of the Spanish Government (MAT2016-78903-R, MAT2016-9 
79435-R, MAT2013-42473-R, MAT2013-41723-R and MAT2012-38043), the Centro 10 
en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, and Junta de 11 
Castilla y León (VA244U13, VA313U14 and GRS/516/A/10), Spain. Sandra Muntión 12 
is supported by grant RD12/0019/0017 from the Instituto de Salud Carlos III, Spain. 13 
CONFLICT OF INTERESTS 14 
The authors have no competing interests to declare. 15 
REFERENCES 16 
1. Bhosale AM, Richardson JB. 2008. Articular cartilage: structure, injuries and 17 
review of management. Br Med Bull 87:77-95. 18 
2. Kuettner KE, Cole AA. 2005. Cartilage degeneration in different human joints. 19 
Osteoarthritis Cartilage 13:93-103. 20 
28 
 
 
3. Maetzel A, Li LC, Pencharz J, et al. 2004. The economic burden associated with 1 
osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. 2 
Annals of the rheumatic diseases 63:395-401. 3 
4. Hiligsmann M, Reginster J-Y. 2013. The economic weight of osteoarthritis in 4 
Europe. Medicographia 35:197-202. 5 
5. Chevalier X. 1998. Physiopathology of arthrosis. The normal cartilage. . Presse 6 
Med 27(2):75-80. 7 
6. Pei M, Yan Z, Shoukry M, et al. 2010. Failure of xenoimplantation using 8 
porcine synovium-derived stem cell-based cartilage tissue constructs for the 9 
repair of rabbit osteochondral defects. J Orthop Res 28:1064-1070. 10 
7. Kerker JT, Leo AJ, Sgaglione NA. 2008. Cartilage repair: synthetics and 11 
scaffolds: basic science, surgical techniques, and clinical outcomes. Sports 12 
Medicine and Arthroscopy 16:208-216. 13 
8. Vaquero J, Forriol F. 2011. Knee chondral injuries: Clinical treatment strategies 14 
and experimental models. Injury. 15 
9. Bartlett W, Gooding CR, Carrington RW, et al. 2005. Autologous chondrocyte 16 
implantation at the knee using a bilayer collagen membrane with bone graft. A 17 
preliminary report. The Journal of bone and joint surgery British volume 87:330-18 
332. 19 
10. Chen F, Rousche K, Tuan R. 2006. Technology Insight: adult stem cells in 20 
cartilage regeneration and tissue engineering. Nature Clinical Practice 21 
Rheumatology 2(7):373-382. 22 
29 
 
 
11. Kessler M, Ackerman G, Dines J, et al. 2008. Emerging technologies and fourth 1 
generation issues in cartilage repair. Sports Medicine and Arthroscopy 2 
16(4):246-254. 3 
12. Li J, Ezzelarab MB, Cooper DKC. 2012. Do mesenchymal stem cells function 4 
across species barriers? Relevance for xenotransplantation. Xenotransplantation 5 
19:273-285. 6 
13. Niemeyer P, Vohrer J, Schmal H, et al. 2008. Survival of human mesenchymal 7 
stromal cells from bone marrow and adipose tissue after xenogenic 8 
transplantation in immunocompetent mice. Cytotherapy 10:784-795. 9 
14. Pei M, Yan Z, Shoukry M, et al. 2010. Failure of xenoimplantation using 10 
porcine synovium-derived stem cell-based cartilage tissue constructs for the 11 
repair of rabbit osteochondral defects. Journal of Orthopaedic Research 28:1064-12 
1070. 13 
15. Revell CM, Athanasiou KA. 2009. Success rates and immunologic responses of 14 
autogenic, allogenic, and xenogenic treatments to repair articular cartilage 15 
defects. Tissue Engineering Part B Reviews 15:1-15. 16 
16. Roche ET, Hastings CL, Lewin SA, et al. 2014. Comparison of biomaterial 17 
delivery vehicles for improving acute retention of stem cells in the infarcted 18 
heart. Biomaterials 35:6850-6858. 19 
17. Martens TP, Godier AFG, Parks JJ, et al. 2009. Percutaneous Cell Delivery Into 20 
the Heart Using Hydrogels Polymerizing In Situ. Cell transplantation 18:297-21 
304. 22 
30 
 
 
18. Girotti A, Orbanic D, Ibáñez-Fonseca A, et al. 2015. Recombinant Technology 1 
in the Development of Materials and Systems for Soft-Tissue Repair. Advanced 2 
Healthcare Materials 4:2423-2455. 3 
19. Rodriguez-Cabello JC, Girotti A, Ribeiro A, et al. 2012. Synthesis of genetically 4 
engineered protein polymers (recombinamers) as an example of advanced self-5 
assembled smart materials. Methods in molecular biology 811:17-38. 6 
20. Rodriguez-Cabello JC, Martin L, Girotti A, et al. 2011. Emerging applications 7 
of multifunctional elastin-like recombinamers. Nanomedicine (London, 8 
England) 6:111-122. 9 
21. Urry DW. 1993. Molecular Machines - How Motion and Other Functions of 10 
Living Organisms Can Result from Reversible Chemical-Changes. Angewandte 11 
Chemie-International Edition in English 32:819-841. 12 
22. Tamburro AM, Guantieri V, Pandolfo L, et al. 1990. Synthetic fragments and 13 
analogues of elastin. II. Conformational studies. Biopolymers 29:855-870. 14 
23. Martin L, Arias FJ, Alonso M, et al. 2010. Rapid micropatterning by 15 
temperature-triggered reversible gelation of a recombinant smart elastin-like 16 
tetrablock-copolymer. Soft Matter 6:1121-1124. 17 
24. Ruoslahti E, Pierschbacher MD. 1986. Arg-Gly-Asp: A versatile cell recognition 18 
signal. Cell 44:517-518. 19 
25. Caumo F, Russo A, Faccioli N, et al. 2007. Autologous chondrocyte 20 
implantation: prospective MRI evaluation with clinical correlation. La radiologia 21 
medica 112:722-731. 22 
31 
 
 
26. Marlovits S, Striessnig G, Resinger CT, et al. 2004. Definition of pertinent 1 
parameters for the evaluation of articular cartilage repair tissue with high-2 
resolution magnetic resonance imaging. European Journal of Radiology 52:310-3 
319. 4 
27. Trattnig S, Millington SA, Szomolanyi P, et al. 2007. MR imaging of 5 
osteochondral grafts and autologous chondrocyte implantation. European 6 
Radiology 17:103-118. 7 
28. Barber FA, Dockery WD. 2011. A computed tomography scan assessment of 8 
synthetic multiphase polymer scaffolds used for osteochondral defect repair. 9 
Arthroscopy 27:60-64. 10 
29. Orth P, Zurakowski D, Wincheringer D, et al. 2011. Reliability, Reproducibility, 11 
and Validation of Five Major Histological Scoring Systems for Experimental 12 
Articular Cartilage Repair in the Rabbit Model. Tissue Engineering Part C: 13 
Methods 18:329-339. 14 
30. Pérez-Simon JA, López-Villar O, Andreu EJ, et al. 2011. Mesenchymal stem 15 
cells expanded in vitro with human serum for the treatment of acute and chronic 16 
graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 17 
96:1072-1076. 18 
31. Villaron E, Almeida J, Lopez-Holgado N, et al. 2004. Mesenchymal stem cells 19 
are present in peripheral blood and can engraft after allogeneic hematopoietic 20 
stem cell transplantation. Haematologica 89:1421-1427. 21 
32 
 
 
32. Conget PA, Minguell JJ. 1999. Phenotypical and functional properties of human 1 
bone marrow mesenchymal progenitor cells. Journal of Cellular Physiology 2 
181:67-73. 3 
33. Beyer Nardi N, da Silva Meirelles L. 2006. Mesenchymal stem cells: isolation, 4 
in vitro expansion and characterization. Handbook of experimental 5 
pharmacology:249-282. 6 
34. Nakamura T, Sekiya I, Muneta T, et al. 2012. Arthroscopic, histological and 7 
MRI analyses of cartilage repair after a minimally invasive method of 8 
transplantation of allogeneic synovial mesenchymal stromal cells into cartilage 9 
defects in pigs. Cytotherapy 14:327-338. 10 
35. Hrabchak C, Rouleau J, Moss I, et al. 2010. Assessment of biocompatibility and 11 
initial evaluation of genipin cross-linked elastin-like polypeptides in the 12 
treatment of an osteochondral knee defect in rabbits. Acta Biomaterialia 6:2108-13 
2115. 14 
36. Nettles DL, Kitaoka K, Hanson NA, et al. 2008. In Situ Crosslinking Elastin-15 
Like Polypeptide Gels for Application to Articular Cartilage Repair in a Goat 16 
Osteochondral Defect Model. Tissue Engineering Part A 14:1133-1140. 17 
37. Schütz K, Despang F, Lode A, et al. 2016. Cell-laden biphasic scaffolds with 18 
anisotropic structure for the regeneration of osteochondral tissue. Journal of 19 
Tissue Engineering and Regenerative Medicine 10:404-417. 20 
38. Marquass B, Somerson JS, Hepp P, et al. 2010. A novel MSC-seeded triphasic 21 
construct for the repair of osteochondral defects. Journal of Orthopaedic 22 
Research 28:1586-1599. 23 
33 
 
 
39. Yang J, Shrike Zhang Y, Yue K, et al. Cell-Laden Hydrogels for Osteochondral 1 
and Cartilage Tissue Engineering. Acta Biomaterialia. 2 
40. Kangarlu A, Gahunia HK. 2006. Magnetic resonance imaging characterization 3 
of osteochondral defect repair in a goat model at 8 T. Osteoarthritis Cartilage 4 
14:52-62. 5 
41. Kim M, Foo LF, Uggen C, et al. 2010. Evaluation of early osteochondral defect 6 
repair in a rabbit model utilizing fourier transform-infrared imaging 7 
spectroscopy, magnetic resonance imaging, and quantitative T2 mapping. Tissue 8 
Engineering Part C Methods 16:355-364. 9 
42. Haleem AM, Singergy AA, Sabry D, et al. 2010. The Clinical Use of Human 10 
Culture-Expanded Autologous Bone Marrow Mesenchymal Stem Cells 11 
Transplanted on Platelet-Rich Fibrin Glue in the Treatment of Articular 12 
Cartilage Defects: A Pilot Study and Preliminary Results. Cartilage 1:253-261. 13 
43. Koga H, Muneta T, Ju YJ, et al. 2007. Synovial stem cells are regionally 14 
specified according to local microenvironments after implantation for cartilage 15 
regeneration. Stem Cells 25:689-696. 16 
44. Mazaki T, Shiozaki Y, Yamane K, et al. 2014. A novel, visible light-induced, 17 
rapidly cross-linkable gelatin scaffold for osteochondral tissue engineering. 18 
Scientific Reports 4:4457. 19 
45. Miller RE, Grodzinsky AJ, Vanderploeg EJ, et al. 2010. Effect of self-20 
assembling peptide, chondrogenic factors, and bone marrow-derived stromal 21 
cells on osteochondral repair. Osteoarthritis and Cartilage 18:1608-1619. 22 
34 
 
 
46. D'Este M, Sprecher CM, Milz S, et al. 2016. Evaluation of an injectable 1 
thermoresponsive hyaluronan hydrogel in a rabbit osteochondral defect model. 2 
Journal of Biomedical Materials Research Part A 104:1469-1478. 3 
47. Levingstone TJ, Thompson E, Matsiko A, et al. 2016. Multi-layered collagen-4 
based scaffolds for osteochondral defect repair in rabbits. Acta Biomaterialia 5 
32:149-160. 6 
48. Pulkkinen HJ, Tiitu V, Valonen P, et al. 2013. Repair of osteochondral defects 7 
with recombinant human type II collagen gel and autologous chondrocytes in 8 
rabbit. Osteoarthritis and Cartilage 21:481-490. 9 
49. Liu S, Jia Y, Yuan M, et al. 2017. Repair of Osteochondral Defects Using 10 
Human Umbilical Cord Wharton&#x2019;s Jelly-Derived Mesenchymal Stem 11 
Cells in a Rabbit Model. BioMed Research International 2017:12. 12 
50. Jang K-M, Lee J-H, Park CM, et al. 2014. Xenotransplantation of human 13 
mesenchymal stem cells for repair of osteochondral defects in rabbits using 14 
osteochondral biphasic composite constructs. Knee Surgery, Sports 15 
Traumatology, Arthroscopy 22:1434-1444. 16 
